Skip to main content
dryadpublic

Data from: Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia

ShareScore

24/100

Overall dataset sharing score

Score breakdown

These five areas show where the dataset supports — or may limit — practical reuse.

Stewardship
0
Harmonization
8
Access
12
Reuse readiness
0
Engagement
4

Dataset details

Repository
dryad
Published
May 29, 2019
License
Not reported
DOI
doi:10.5061/dryad.vg6jp14

Scored with release 0.9.0

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.